Citations

Clear

371 citation(s) found for "Cho, B".

Source‐free domain adaptation for multi‐institutional chest X‐ray images
Kim, Hyoyi , Lee, Seoyoung, Cho, S, Cho, Seungryong

Mayo Clinic

Journal of Applied Clinical Medical Physics | May 23, 2026 | Volume: 27 | Issue: 5 | Pages: No page available

10.1002/acm2.70626 | PMID 42176315 Get It

Abstract Background Machine learning models for chest X‐ray (CXR)‐based tuberculosis (TB) detection often suffer from performance drops when deployed across institutions due to domain shifts caused by differences in patient populations, imaging protocols, and equipment. Domain adaptation has been widely studied to address the problem, but privacy regulations restrict data sharing, making conventional approaches infeasible. Purpose We aim to enhance TB detection performance when a detector model is shared across multiple clinical sites without accessing any source data or statistics. This problem is related to source‐free domain adaptation (SFDA) but requires special designs for imbalanced binary classification. Methods We propose two methods for TB detection, which are based on Source HypOthesis Transfer (SHOT) and SFDA via source Distribution Estimation (SFDA‐DE), respectively. As the main ideas of our methods, we propose ranking‐based pseudo‐labeling and selective fine‐tuning of network layers to address severe class imbalance and prevent overfitting. Results On six unseen target domains with high class imbalance, our proposed SFDA methods significantly improved the average F1 score and AUROC compared to non‐adapted models, all without accessing source data during adaptation. Conclusions Our methods offer a privacy‐preserving and effective strategy to improve the generalization of TB detection models across institutions, addressing domain shifts while complying with data‐sharing restrictions.
D22-04 Demographics, Disparities, and Donor Dynamics: A Comprehensive Evaluation of US Lung Transplant Trends (1988-2025)
Chinnamuthu, R, Bohra, R, Fernandes, W, Fernandes, B C, Cho, T, Phadke, R, Senthilkumar, V, Geetha, H Shanmugavel, Chinnamuthu, Rajaeaswaran, Bohra, Rhea, Fernandes, Bolivia Crocete Aloysia, Phadke, R, Geetha, Harinivaas Shanmugavel

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.6657 Get It

Abstract Purpose This analysis aims to provide a comprehensive overview of lung transplantation trends in the United States from January 1, 1988, through January 31, 2025. By examining key variables such as recipient ABO blood group, donor type (deceased or living), demographic factors, and geographic distribution, the goal is to highlight the evolution and current state of lung transplantation practices. Methods Data were obtained from the Organ Procurement and Transplantation Network (OPTN), encompassing all reported lung transplants during the specified time period. Relevant metrics included the number of transplants per year, recipient characteristics (blood type, race/ethnicity, gender, and age), donor type (deceased versus living), and state-level transplant volumes. Simple descriptive statistics (e.g., frequencies and percentages) were used to identify trends and capture the distribution of transplants among different demographic groups and geographic regions. Results A total of 55,435 lung transplants were performed in the United States between 1988 and early 2025. The vast majority (over 99%) utilized deceased donors, underscoring the limited role of living-donor lobar transplantation, with only 253 procedures reported nationally. Among recipients, ABO blood group O was the most common (∼45%), followed by group A (∼40%), group B (∼11%), and group AB (∼4%). Male recipients represented approximately 57% of transplants, while females accounted for 43%. Regarding race/ethnicity, White non-Hispanic patients constituted roughly 80% of all recipients, with Black non-Hispanic (8%) and Hispanic/Latino (8%) recipients forming smaller but significant proportions. Age distribution data revealed that individuals aged 50 to 64 years received nearly half of all lung transplants, and those over 65 years composed about a quarter of total recipients, reflecting a gradual shift in acceptance criteria favoring older adults. Geographically, California reported the highest volume of lung transplants, attributable to its large population and multiple high-volume transplant centers, while other states such as Florida, Ohio, North Carolina, and Missouri also demonstrated notable activity. Conclusion Lung transplantation in the United States has witnessed substantial expansion in both volume and scope since 1988, with the majority of procedures involving deceased donor lungs. A small number of living-donor lung transplants, while demonstrating innovative clinical possibilities, remains limited. The demographic profile of recipients continues to shift, evidenced by a growing proportion of older adults and a predominance of ABO type O and White, non-Hispanic recipients. Despite these advancements, persistent gaps in access, particularly among underrepresented racial and ethnic groups, highlight the need for further refinement in organ allocation policies and broader support services. This abstract is funded by: None
Resolving inflammatory bowel disease risk variants to genes and cell types
Zhang, Rui, Gettler, Kyle , Haritunians, Talin , Cleynen, Isabelle , Stevens, Christine R , Zhang, Qian , Tastad, Christopher, Medici, Catalina, Abreu, María T. , Achkar, Jean-Paul, Ahmad, Tariq, Bernstein, Charles, Brooks, Johanne , Bujanda, Luis, Butterworth, Jeffrey, Clark, Katie, Cummings, F, Buono, Joanne Del, Foley, Stephen, Franchimont, Denis , Hancock, L, Hart, Ailsa, Hooper, Patricia, Jarvis, Mark , Johnston, EL, Kemp, Cheryl, Kennedy, Nick, Lewis, James D. , Li, Andy, Louis, Édouard , Moayyedi, Paul, Moran, G , Newman, Bill, Oglesby, Arabis, Pekow, Joel, Perez, Kate J., Pollok, R, Radford-Smith, Graham , Raffals, L, Raine, Tim, Ramadas, Arvind, Ramakrishnan, S., Reinisch, Walter , Satsangi, Jack, Selinger, Christian, Shedwell, Sophy, Silverberg, Mark S. , Singh, Salil, Steel, Alan, Uhlig, Holm H. , Verma, Ajay, Weersma, Rinse K. , Xavier, Ramnik, Parkes, M, Lee, James C. , McGovern, D, Anderson, Carl A. , Lee, James , Raine, Tim , Zhang, Rui , Haritunians, Talin , Raine, Tim , Anderson, Carl A , Fachal, Laura , Cleynen, Isabelle , Stevens, Christine R. , Zhang, Qian , Tastad, Christopher , Do, Ron , Achkar, Jean–Paul , Ahmad, Tariq , Kok, Klaartje Bel , Butterworth, Jeffrey R., Cummings, Fraser , D’Amato, Mauro , Duerr, Richard H , Ellinghaus, David , Franchimont, Denis , Franke, André , Hart, Ailsa , Hooper, Patricia, Irving, Peter Miles , Julià, Antonio , Kennedy, Nicholas Alexander , Kupcinskas, Juozas , Latiano, Anna , Lewis, James D , McLaughlin, John , Moayyedi, Paul , Mowat, Craig , Newberry, Rodney D. , Perez, Kate J, Prescott, Natalie , Radford‐Smith, Graham L , Raffals, Laura E. , Reinisch, Walter , Rogler, Gerhard , Sands, Bruce E , Satsangi, Jack, Scharl, Michael , Schreiber, Stefan , Sebastian, Shaji , Selinger, Christian P. , Steed, Helen , Vermeire, Séverine , Halfvarson, Jonas , Daly, Mark J. , Lamb, Christopher A , Huang, Hailiang , McGovern, Dermot P.B. , Rioux, John D. , Cho, Judy H , Zhang, Rui

Mayo Clinic

No container title available | May 18, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.64898/2026.05.13.26352926 Get It

Abstract Inflammatory bowel diseases (IBD), principally Crohn’s disease (CD) and ulcerative colitis (UC), are common chronic disorders involving inflammation and often progressive tissue damage. Genome-wide association studies have mapped many risk signals, but the causal variants, effector genes and relevant cellular contexts remain difficult to resolve, limiting mechanistic interpretation and therapeutic translation. Here we performed a multi-ancestry GWAS meta-analysis of 125,992 individuals with IBD and more than 1.2 million controls, identifying 619 independent association signals (374 novel) at 420 IBD regions that account for 77–80% of SNP-based heritability. Fine-mapping resolved 81 high-confidence variants, 41 not previously reported. Although most signals were shared between CD and UC, 39% showed IBD subtype specificity, with UC signals showing stronger enrichment in functional annotations from intestinal epithelial, secretory and enteroendocrine cells, and CD showing stronger genetic correlations with circulating inflammatory biomarkers, including C-reactive protein and glycoprotein acetylation. Latent causal modelling supported a causal effect of decreased high-density lipoprotein on CD risk. By integrating bulk and single-cell eQTL and pQTL resources using colocalisation and Mendelian randomisation, together with coding-variant evidence from exome sequencing, we prioritised 664 candidate effector genes across 341 signals, including 390 newly implicated IBD genes, revealing new biological mechanisms and candidate therapeutic targets supported by human genetics.
A15-01 Proteins Associated With Severity and Mortality in Interstitial Lung Abnormalities
Rose, J A, Bjarnadottir, H, Zhang, J, Moll, M, Gudmundsdottir, V , Tukpah, A -M C, Cutting, C, FInkel, N, Nishino, M, Gudmundsson, G, Pratte, K A, Kim, J, Ortega, V E, Raby, B A, Rosas, I O, Barjaktarevic, I, Washko, G R, Silverman, E K, Lynch, D A, Choi, S, Bowler, R P, Putman, R K, Hatabu, H, O’Connor, G T, Gudnason, V, Cho, M H, Hunninghake, G M, Guðmundsson, Gunnar , Bjarnadóttir, Helga , Cutting, Claire C. , Finkel, Nancy , Nishino, Mizuki , Pratte, K.A., Lynch, David A. , Putman, Rachel K. , Hatabu, Hiroto , Cho, Michael H. , Hunninghake, G.M.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2199 Get It

Abstract Rationale Interstitial lung abnormalities (ILA) are abnormal findings on chest CT scans that may represent early-stages of interstitial lung disease. The presence of fibrosis (traction bronchiectasis and/or honeycombing) identifies those with ILA at an increased risk for mortality, however, determining who will progress remains a challenge, and the role of blood-based biomarkers in ILA risk-stratification is unknown. Methods Data from four prospective cohort studies were used to identify associations between plasma proteins measured with DNA aptamers (SomaScan) and ILA, fibrosis, and mortality. The Genetic Epidemiology of COPD Study (COPDGene) was used to identify protein associations, and findings were replicated by meta-analysis of the Age, Gene/Environment Susceptibility-Reykjavik study (AGES-Reykjavik), SubPopulations and InteRmediate Outcome Measures in COPD Study (SPIROMICS), and Framingham Heart Study (FHS). Protein associations with ILA and with fibrotic ILA compared to non-fibrotic ILA were performed using multivariable logistic regression; among those with ILA, Cox proportional hazards models were used to identify protein associations with mortality. Models were adjusted for age, gender, race, BMI, smoking status, pack-year smoking history, and for mortality, COPD. Benjamini-Hochberg false discovery rate p-values <0.05 were considered significant. Results 524 (10.7%) of 4,899 COPDGene participants had ILA, of whom 57 (10.9%) had fibrosis; of 8,146 AGES-Reykjavik, SPIROMICS and FHS participants included in the meta-analysis, 666 (8.2%) had ILA, of whom 198 (29.7%) had fibrosis. In COPDGene, 230 proteins were associated with ILA; the most significant of which were SFTPD (adjusted odds ratio per standard deviation [SD] of protein [OR]=2.21, p = 3.7E-41) and SFTPB (OR = 1.82, p = 7.9E-37). In the meta-analysis, 159 of the ILA-associated proteins were replicated. Of the 230 ILA-associated proteins in COPDGene, 9 were associated with fibrosis, and 5 of these 9 proteins were associated with mortality among those with ILA. The 5 proteins associated with all three outcomes were WFDC2 (ORILA=1.90, p = 2.6E-34; ORFibrosis=2.00, p = 0.0001; adjusted hazards of mortality per SD of protein [HR]=1.59, p = 3.4E-05), GDF15 (ORILA=1.67, p = 3.6E-23; ORFibrosis=1.78, p = 0.0006; HR = 1.63, p = 1.4E-06), SCGB3A1 (ORILA=1.52, p = 4.5e-14; ORFibrosis=1.80, p = 0.0002; HR = 1.25, p = 0.02), TREM1 (ORILA=1.44, p = 1.4e-14; ORFibrosis=1.62, p = 0.001; HR = 1.25, p = 0.02) ICAM5 (ORILA=1.42, p = 1.2e-11; ORFibrosis=1.79, p = 0.0001; HR = 1.31, p = 0.002). In the meta-analysis, 6 of the 9 fibrosis-associated proteins and all 5 ILA mortality-associated proteins replicated. Conclusion This represents the first plasma proteomic screen demonstrating reproducible biomarker associations not only with ILA presence, but also with measures of severity and adverse outcomes. These results provide compelling targets for further study, including their prospective evaluation as clinical biomarkers for early disease identification and prognostication. This abstract is funded by: Multiple Sources
C101-06 Interactions of Leukotriene-B4 and Interleukin-8 Gene Variants and Protein Levels With PI*MZ Heterozygosity Among the COPDGene and SPIROMICS Cohorts
Tejwani, V, Bazeley, P, Barjaktarevic, I, Barnard, J, Bleecker, E R, Cho, M H, Curtis, J L, Moll, M, Meyers, D A, Ruvuna, L, Shrivastav, A, Siddharthan, T, Silverman, E K, Stoller, J K, Zhang, J, Bowler, R P, Zein, J G, Hersh, C P, Ortega, V E, Bazeley, Peter , Cho, Michael H. , Curtis, Jeffrey L. , Meyers, Deborah A. , Ruvuna, L. , Stoller, James K. , Zein, Joe , Hersh, Craig P.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.2025 Get It

Abstract Rationale Deficiency of alpha-1 antitrypsin (AAT), the protein encoded by SERPINA1, remains the strongest genetic risk factor for COPD. Individuals heterozygote for the type Z variant, termed the PI*MZ genotype (estimated global prevalence n = 35,000,000), experience varying respiratory morbidity beyond expected from tobacco smoking alone. AAT is a pleiotropic protein which inhibits not only neutrophil elastase but also neutrophil chemotaxis mediated by leukotriene B4 (LTB4) [by antagonizing the LTB4 receptor (LTB4R)] and interleukin-8 (IL-8). Although LTB-4 and IL-8 gene variants and protein levels have independently been implicated in COPD, their potential role in PI*MZ is unknown. Methods COPDGene and SPIROMICS are observational tobacco-smoke and COPD-enriched cohort studies. Participants were phenotyped by spirometry and CT imaging, with whole genome sequencing data available via TOPMed. We analyzed participants with PI*MM (COPDGene n = 9,732; SPIROMICS n = 2,105) and PI*MZ (COPDGene n = 300; SPIROMICS n = 83). LTB-4 (ALOX5AP, LTA4H, LTB4R) and IL-8 (CXCL8, CXCR1, CXCR2) associated gene variants (exonic and intronic) with a minor allele frequency of ≥ 0.05 were extracted. We assessed statistical interactions between MZ status and chest CT outcomes or FEV1% predicted using the SPAGxECCT package with adjustment for relatedness (genetic related matrix) and ancestry (top ten PCs). Baseline protein LTB4R (SPIROMICS only) and IL-8 (both cohorts) protein levels were measured via SomaScan, and statistical interactions between MZ status and AAT concentration were explored. Models were adjusted for age, sex, BMI, smoking status, and pack-years. Given the candidate gene discovery approach, significance was defined as nominal p-value<0.05 Results We identified the following number of variants in genes of the LTB-4 or IL-8 pathways: 87 shared between cohorts; 133 unique to COPDGene; 1 unique to SPIROMICS. LTB-4-related polymorphisms were associated (p < 0.05) with any radiographic outcomes in 22 variants (COPDGene) vs. 23 variants (SPIROMICS), with a single overlap (rs17074984 in ALOX5AP). Two LTB-4-pathway variants were associated with FEV1% predicted in SPIROMICS (both in ALOX5AP), but none in COPDGene. AAT plasma concentrations displayed a statistically significant interaction with FEV1% predicted (p = 0.046) and PRMemphysema (p = 0.013) for LTBR4, but not for IL-8. There was not an interaction by MM/MZ status and protein levels. Conclusions Predominantly LTB-4, and not IL-8, pathway-related genetic variants and protein levels may contribute to disease heterogeneity among PI*MZ individuals. The association of circulating LTB4R protein with reduced lung function, particularly among those with low AAT levels, further suggest interactions between AAT and the leukotriene pathway in PI*MZ individuals. Thus, PI*MZ individuals may uniquely derive benefit from leukotriene-targeting pharmacotherapy. This abstract is funded by: NIH NHLBI K23HL173570
B109-09 Multi-Trait Polygenic Scores for COPD and COPD Exacerbations Implicate Druggable Proteins
Zhang, C , Konigsberg, I R, He, Y, Zhang, J, Chikowore, T, Feldman, W B, Hu, X, Ding, Y, Pasaniuc, B, Chang, D, Chen, Q, Lasky-Su, J A, Hecker, J, Tobin, M D, Chen, J, Kalra, S, Pratte, K A, Im, H K , Wan, E S, Manichaikul, A W, Silverman, E K, Bowler, R P, Lange, L A, Ortega, V E, Martin, A R, Cho, M H, Moll, M R, Konigsberg, Iain R. , Paşaniuc, Bogdan , Lasky‐Su, Jessica , Kalra, S. , Pratte, K.A., Wan, Emily S. , Silverman, Edwin K. , Bowler, R P, Moll, Matthew

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1934 Get It

Abstract Rationale To construct multi-trait polygenic scores (PRS) predicting chronic obstructive pulmonary disease (COPD) and exacerbations, validate their performance in diverse cohorts, and identify PRS-related proteins for potential therapeutic targeting. Methods PRSmix+, a multi-trait PRS framework, is used to train a composite PRS (PRSmulti) in COPDGene non-Hispanic white participants (n = 6,647). Associations of PRSmulti with COPD status (GOLD 2-4 vs. GOLD 0 or ICD) and exacerbation frequency were tested in COPDGene African American (n = 2,466), ECLIPSE (n = 1,858), MassGeneral Brigham Biobank (n = 15,152), and All of Us (n = 118,566). Protein prediction models were applied to GWAS summary statistics from traits contributing to PRSmulti and were validated with proteomic data in COPDGene (n = 5,173) and UK Biobank (n = 5,012). Results PRSmix+ selected 7 traits for PRSmulti. In multivariable models, PRSmulti was associated with COPD status (meta-analysis random effects (RE) OR 1.58 [95% CI: 1.28-1.94]) and exacerbation frequency (meta-analysis RE beta 0.21 [95% CI: 0.11-0.31]), with higher effect sizes observed in smoking-enriched cohorts. PRSmulti outperformed traditional single-trait PRS in all tested cohorts. Using protein prediction models, we identified 73 proteins associated with the PRS that were also validated with measured protein levels in COPDGene and UK biobank. Of these proteins, 25 were linked to approved or investigational drugs. Notable targets include AGER (RAGE), IL1RL1, and SCARF2, all implicated in COPD pathogenesis and exacerbations. Conclusions Multi-trait PRS improves prediction of COPD and exacerbation risk. Integration with proteomic data identifies druggable protein targets, offering a promising avenue for precision medicine in COPD management. Trial registration. COPDGene: NCT00608764; ECLIPSE: NCT00292552. This abstract is funded by: NIH and the COPD Foundation
A101-20 Polygenic Risk Score and Cigarette Smoking Modify Risk of Airflow Obstruction in Individuals With Alpha-1 Antitrypsin MZ Genotype
Zhang, J, Moll, M, Choi, S, Tejwani, V, Ortega, V E, Wilson, A A, Dupuis, J, Cho, M H, O’Connor, G T, Cho, Michael H.

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.1737 Get It

Abstract Rationale Alpha-1 antitrypsin (AAT) deficiency, primarily caused by homozygous SERPINA1 Z mutation, increases the risk of COPD. Individuals carrying one Z and one normal M allele (MZ) have higher COPD risk than MM individuals, although many never develop disease. COPD is a polygenic condition influenced by numerous genetic factors across the genome and by environmental exposures such as smoking. We aimed to examine how polygenic factors and smoking modify risk of airflow obstruction in MZ compared with MM. Methods We included participants with the MZ and MM genotypes from the Framingham Heart Study. We first tested the association between AAT genotype (MZ coded as 1 and MM as 0) and FEV1/FVC, stratified by ever-smoking status, and further evaluated interactions between AAT genotype and smoking pack-years. Next, for each participant we calculated a polygenic risk score (PRS) for FEV1/FVC, which was derived from external genome-wide association studies in the UK Biobank and SpiroMeta Consortium. To reflect risk for airflow limitation, higher PRSs correspond to lower FEV1/FVC. We then tested the interaction between the PRS and AAT genotype, stratified by ever-smoking. Models were adjusted for age, sex, height, current smoking, pack-years (among ever-smokers), familial relatedness, and in PRS models, principal components of genetic ancestry. Results Among 4,220 participants (mean age 53.7 years, 54.2% female, 50.2% ever-smokers, mean FEV1/FVC 74.6%), 133 (3.2%) had MZ genotype. In never-smokers, MZ individuals had 1.72% higher FEV1/FVC compared with MM (P = 0.032), whereas no difference was observed among ever-smokers (β= -0.39%; P = 0.65). Cumulative smoking modified the effect of MZ genotype on FEV1/FVC (interaction β= -0.13% per pack-year; P = 0.003); this interaction persisted among ever-smokers (β= -0.11% per pack-year; P = 0.044). A one-standard-deviation increase in the FEV1/FVC PRS was associated with lower FEV1/FVC in both never- (β= -2.37%; P < 0.0001) and ever-smokers (β= -2.46%; P < 0.0001). A higher PRS was disproportionately associated with reduced FEV1/FVC in MZ compared to MM (interaction β= -1.87% per standard-deviation PRS increase, P = 0.027) among ever-smokers, but not in never-smokers (P = 0.15). Conclusions In this community-based cohort, the AAT MZ genotype was associated with higher FEV1/FVC among non-smokers compared to MM. The interaction between MZ genotype and pack-years suggested a dose-dependent modifying effect of smoking on the MZ-related COPD risk. Among ever-smokers, higher polygenic risk further amplified susceptibility to airflow obstruction in MZ compared with MM. These findings highlight the roles of both polygenic and environmental risk factors in COPD susceptibility in MZ. Replication of the results is needed. This abstract is funded by: This work is supported by an Alpha-1 Foundation Grant and a Boston University Department of Medicine Career Investment Award
A105-21 Mapping Health Disparities: Pneumonia and Chronic Kidney Disease Mortality Across Demographics
Chinnamuthu, R, Bohra, R, Fernandes, W, Fernandes, B C, Cho, T, Senthilkumar, V, Phadke, R, Lim, A, Geetha, H Shanmugavel, Chinnamuthu, Rajaeaswaran, Bohra, Rhea, Fernandes, Bolivia Crocete Aloysia, Phadke, R, Geetha, Harinivaas Shanmugavel

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.922 Get It

Abstract Purpose This study aimed to analyze mortality trends among patients with pneumonia and chronic kidney disease in the United States from 1999 to 2020. By examining patterns across urbanization levels, racial and ethnic groups, geographic regions, and sex, the study sought to identify significant changes over time and potential disparities in mortality outcomes. Methods Mortality data were extracted from the CDC WONDER database for patients diagnosed with pneumonia (ICD-10: J09-J18) and chronic kidney disease (ICD-10: N18). Trends were analyzed using Annual Percent Change (APC) with 95% confidence intervals (CI). Joinpoint regression was utilized to identify significant shifts in mortality trends over time. The analysis was stratified by urbanization level (Large Central Metro, Large Fringe Metro, Medium Metro, Small Metro, Micropolitan), ethnicity (American Indian or Alaska Native, Asian or Pacific Islander, Black or African American, White), census region (Northeast, Midwest, South, West), Hispanic origin (Hispanic or Latino, Not Hispanic or Latino), and sex (Female, Male). Results From 2018 to 2020, significant increases in mortality were observed across all demographic and geographic categories. Urban areas, particularly Large Central Metro (APC = 39.4026%, p = 0.0008) and Small Metro (APC = 37.0284%, p = 0.0004), experienced the most pronounced rises. Ethnic disparities were evident, with Black or African American (APC = 49.9199%, p < 0.000001) and Hispanic or Latino (APC = 61.5742%, p < 0.000001) populations showing the highest mortality increases. By census region, the Midwest (APC = 35.7843%, p = 0.0004) and South (APC = 34.7972%, p = 0.0016) had the most significant spikes. Both females (APC = 36.0664%, p = 0.0004) and males (APC = 35.1504%, p < 0.000001) experienced substantial mortality increases, with females showing slightly higher rates. Conclusion The findings reveal significant increases in mortality from 2018 to 2020 across all analyzed categories, with notable disparities among racial, ethnic, and geographic groups. These trends highlight the need for further investigation into underlying causes and targeted interventions to address inequities. Clinical implications The results underscore the importance of addressing disparities in healthcare access and outcomes, particularly for Black or African American and Hispanic or Latino populations. Clinicians should focus on early diagnosis, effective management of comorbidities, and equitable resource distribution to mitigate mortality risks in high-risk groups. This abstract is funded by: None
C55-32 Temporal Trends and Racial Disparities in ARDS Mortality Location in the United States (2003-2020)
Lim, A, Mee, X, Lim, G, Phang, C, Cho, T

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | May 18, 2026 | Volume: 212 | Issue: Supplement_1 | Pages: No page available

10.1093/ajrccm/aamag162.203 Get It

Abstract Aim Acute respiratory distress syndrome (ARDS) is a life-threatening condition frequently managed in intensive care units, with high in-hospital mortality. Less is known about where mortality happens once care transitions beyond hospital. This study aimed to assess national trends in the location of ARDS-related deaths in the U.S. from 2003 to 2020 to evaluate racial and ethnic disparities in end-of-life settings. Methods A retrospective analysis was performed using Centers for Disease Control and Prevention’s Wide-Ranging Online Data for Epidemiologic Research (CDC WONDER) death certificate data from 2003 to 2020 for all decedents with ARDS (ICD-10 code J80) within the U.S. The proportion of deaths by location (medical facility, decedent’s home, hospice facility, nursing home/long-term care, and other/unknown) was calculated for each year. Linear regression was used to evaluate temporal trends in the proportion of deaths across the study period. Odds ratios (ORs) were calculated using 2 × 2 contingency tables to compare the likelihood of dying in a specific location (e.g., hospice facility, medical facility) between racial and ethnic groups. Results There were 29,028 ARDS deaths in the U.S. from 2003 to 2020. The majority (95.52%) of deaths occurred in medical facilities, with smaller proportions at nursing facilities (1.52%), home (1.50%), hospice (0.69%), other locations (0.33%), and unknown (0.43%). There were no significant changes in the proportions of deaths occurring in medical facilities, decedents’ homes, or nursing homes/long-term care facilities (P > .05 for all). However, the proportion of ARDS deaths occurring in hospitals increased significantly among Black (0.73% to 0.78% (P < .03)) and Asian/Pacific Islander patients (0.12% to 0.19% (P < .01)). Black patients had higher odds of dying in a medical facility compared to White patients (OR = 3.44). No ARDS decedents in the Asian or American Indian groups died outside a medical facility, yielding ORs that approached infinity for these groups. Conclusion The location of ARDS deaths in the U.S. remained largely constant from 2003 to 2020, with most patients dying in hospital settings. This highlights the severity of ARDS and its high in-hospital mortality, reflecting that intensive care is typically required for management. Despite advances in supportive therapies, the persistently high rate of in-hospital deaths suggests limited improvements in out-of-hospital transitions. This study also identified racial disparities. Black patients had higher odds of dying in medical facilities compared to White patients, suggesting inequities in access to home-based end-of-life care options. This abstract is funded by: None
NCCN Guidelines® Insights: Prostate Cancer, Version 5.2026
Spratt, Daniel E., Srinivas, Sandy, Ahmed, Bilawal, An, Yi , Bitting, Rhonda, Chapin, Brian, Cheng, Heather H., D’Amico, Anthony Victor, Desai, Neil, Dorff, T. B., Eastham, James A., Farrington, Thomas A., Gao, Xin, Gupta, S, Karnes, R. Jeffrey, Kishan, Amar U., Kuettel, Michael, Lang, J., Lee, Daniel, Lotan, Tamara, McDonald, Andrew, Morgan, Todd M. , Pessoa, Rodrigo, ROACH, M, Robin, Tyler, Rosenfeld, Stan, Scarpato, Kristen R., Seibert, Tyler, Shabsigh, Ahmad, Szmulewitz, Russell, Tward, Jonathan, Valicenti, Richard, VanderWeele, David, Wong, J.K. , Kovách, E, Freedman-Cass, Deborah, Morgan, Todd M , Robin, Tyler P. , Spratt, Daniel E. , Adra, Nabil , Bitting, Rhonda L. , Chapin, Brian F. , Cheng, Heather H., Cho, Steve Y. , D’Amico, Anthony V. , Dorff, Tanya B. , Eastham, Jeff , Gupta, Shilpa , Ippolito, Joseph E. , Kishan, Amar U. , McDonald, Andrew M. , Rais‐Bahrami, Soroush , Roach, Mack , Scarpato, Kristen R., Shabsigh, Ahmad , Szmulewitz, Russell Z , Teply, Benjamin A. , Tward, Jonathan D. , Valicenti, Richard K., VanderWeele, David James , Freedman-Cass, Deborah A.

Mayo Clinic

Journal of the National Comprehensive Cancer Network | May 14, 2026 | Volume: 24 | Issue: 5 | Pages: 140-149

10.6004/jnccn.2026.0023 | PMID 42134408 Get It

The NCCN Guidelines for Prostate Cancer include recommendations for staging and risk assessment after a prostate cancer diagnosis and for the care of patients with localized, regional, recurrent, and metastatic disease. These NCCN Guidelines Insights summarize the panel’s discussions on select 2026 updates to the guidelines regarding nonmetastatic disease: the elimination of the very-low-risk group, updates to the Principles of Active Surveillance, and caution in the use of focal therapy in newly diagnosed patients.